Prices of common drugs for cancer, multiple sclerosis and other conditions can vary widely depending on the hospital where they're administered, research firm 3 Axis Advisors said in a new report. Why ...

Pharmacy benefit managers (PBMs) have used market leverage to demand rebates, which can lead drug manufacturers to increase sticker prices.

Cancer drug costs are skyrocketing – this we know. But what if we’ve got a distorted view of the overall picture of cancer costs? That’s the argument of Dr. Andrew Pecora, an oncologist and chief ...

The price for the same prescription drug in different hospitals nationwide could have more than a $10,000 difference, according to a new report. A report from 3 Axis Advisors used publicly available ...

Pharmacy benefit managers act as middlemen between drugmakers, insurers, pharmacies and patients and are accused of selling marked-up medicine.

Price transparency compliance is often “in-form” rather than “in-spirit,” with many machine-readable files failing to provide complete, accurate, and usable drug pricing data. Reform priorities ...

Some hospitals in the Netherlands are paying up to €2,800 more than others for the same cancer medicines, according to research examining how oncology drugs are priced across European ...

But the FDA’s decision does not preclude CMS from determining that the higher dose is not reasonable and necessary — ...

Add Yahoo as a preferred source to see more of our stories on Google. Pharmaceutical companies hiked prices on hundreds of drugs so far in January, ushering in 2026 with steeper costs for everything ...

The new cycle of Medicare drug price negotiations includes 15 high-cost drugs, with some covered under Medicare Part B for the first time. The negotiations, part of the Inflation Reduction Act, aim to ...